Summary
The AI response contains many specific renal-dosing and other regimen/monitoring claims that are not supported by the provided JYLAMVO prescribing information excerpts. The supplied label text also does not include the mentioned comparison drugs, vaccine guidance, or eGFR/CrCl thresholds. Multiple statements therefore cannot be validated and represent label-discrepancy risk.
Category Scores
Accurate Statements
Methotrexate can cause renal toxicity, including irreversible acute renal failure.
Section 5.8 Renal Toxicity ("Methotrexate can cause renal toxicity, including irreversible acute renal failure.")
Methotrexate can cause myelosuppression/pancytopenia.
Section 5.3 Myelosuppression ("can cause severe and life-threatening pancytopenia...")
Methotrexate can cause pulmonary toxicity (interstitial pneumonitis) and neurotoxicity.
Sections 5.6 Pulmonary Toxicity and 5.12 Neurotoxicity
Unsupported Statements
Methotrexate has renal clearance.
Not stated in the provided prescribing information excerpts.
Toxicity risk from methotrexate increases with age-related GFR decline.
Not supported by the provided label excerpts.
Guidelines from the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) recommend dose adjustments or switches for creatinine clearance <60 mL/min.
Not part of the provided JYLAMVO label text.
In creatinine clearance <60 mL/min, priority is given to drugs with non-renal elimination or lower nephrotoxicity.
Not stated in the provided label excerpts.
For mild impairment (eGFR 30-59 mL/min), methotrexate dose should be reduced or methotrexate can be switched to leflunomide or sulfasalazine.
No eGFR/CrCl threshold-based dosing or switches to leflunomide/sulfasalazine are included in the provided label excerpts.
For moderate-severe impairment (eGFR <30 mL/min), methotrexate should be avoided.
No eGFR/CrCl threshold-based avoidance guidance appears in the provided label excerpts.
For eGFR <30 mL/min, biologics such as TNF inhibitors (e.g., etanercept) or IL-6 blockers (e.g., tocilizumab) are favored.
Not addressed in the provided JYLAMVO label excerpts.
Tocilizumab is dosed by weight and not by GFR.
Not part of the JYLAMVO prescribing information excerpts.
Live vaccines should be avoided with biologics.
Not included in the provided JYLAMVO label excerpts.
Hydroxychloroquine for RA and lupus requires no adjustment.
Not included in the provided JYLAMVO label excerpts.
Hydroxychloroquine has hepatic clearance.
Not included in the provided JYLAMVO label excerpts.
Hydroxychloroquine can cause retinal toxicity.
Not included in the provided JYLAMVO label excerpts.
Retinal toxicity from hydroxychloroquine is rare and yearly screening is recommended.
Not included in the provided JYLAMVO label excerpts.
Leflunomide for RA: dose should be reduced if eGFR <50.
Not included in the provided JYLAMVO label excerpts.
Leflunomide should be monitored for blood pressure.
Not included in the provided JYLAMVO label excerpts.
Leflunomide can cause diarrhea.
Not included in the provided JYLAMVO label excerpts.
Leflunomide can cause hypertension.
Not included in the provided JYLAMVO label excerpts.
Leflunomide can cause hepatotoxicity.
Not included in the provided JYLAMVO label excerpts.
Sulfasalazine for RA and IBD: dose should be reduced if eGFR <30.
Not included in the provided JYLAMVO label excerpts.
Sulfasalazine is mostly excreted via the gastrointestinal tract.
Not included in the provided JYLAMVO label excerpts.
Sulfasalazine can cause rash.
Not included in the provided JYLAMVO label excerpts.
Sulfasalazine can cause nausea.
Not included in the provided JYLAMVO label excerpts.
Sulfasalazine has sulfa allergy risk.
Not included in the provided JYLAMVO label excerpts.
Etanercept (Enbrel) for RA, PsA, and AS requires no renal adjustment.
Not included in the provided JYLAMVO label excerpts.
Etanercept can cause infections.
Not included in the provided JYLAMVO label excerpts.
Etanercept can cause injection reactions.
Not included in the provided JYLAMVO label excerpts.
Adalimumab (Humira) for RA and Crohn's requires no adjustment.
Not included in the provided JYLAMVO label excerpts.
Adalimumab is cleared via receptors.
Not included in the provided JYLAMVO label excerpts.
Adalimumab has similar infection risk and side effects to etanercept.
Not included in the provided JYLAMVO label excerpts.
Tuberculosis screening is required with adalimumab.
Not included in the provided JYLAMVO label excerpts.
Tocilizumab (Actemra) for RA and GCA requires no adjustment below eGFR 30.
Not included in the provided JYLAMVO label excerpts.
Tocilizumab can cause infections.
Not included in the provided JYLAMVO label excerpts.
Tocilizumab can cause elevated cholesterol.
Not included in the provided JYLAMVO label excerpts.
JAK inhibitors like tofacitinib require eGFR >40-60 mL/min.
Not included in the provided JYLAMVO label excerpts.
MTX nephrotoxicity can present with cytopenias.
Label excerpt confirms myelosuppression exists, but does not link renal toxicity to cytopenias specifically.
Methotrexate nephrotoxicity can present with mucositis.
Not supported by the provided label excerpts.
Methotrexate can cause acute kidney injury from crystal nephropathy.
Not stated in the provided label excerpts.
Monitoring of CBC, LFTs, and creatinine monthly is recommended for methotrexate.
The provided label excerpts do not specify a monthly monitoring cadence for CBC/LFT/creatinine.
Folinic acid supplementation is used to mitigate methotrexate toxicity.
Not included in the provided label excerpts.
Switching promptly is recommended if eGFR drops 20-30% on methotrexate.
Not included in the provided label excerpts.
Biologics like etanercept have lower infection risk in renal impairment compared to JAKs.
Not included in the provided label excerpts.
JAK inhibitors such as baricitinib are avoided if eGFR <30.
Not included in the provided label excerpts.
Biosimilars (e.g., adalimumab-afzb) reduce costs by 20-80% without efficacy loss.
Not included in the provided label excerpts.
Apremilast (Otezla) suits mild cases.
Not included in the provided label excerpts.
Apremilast requires no renal adjustment.
Not included in the provided label excerpts.
Humira (adalimumab) U.S. exclusivity ended in 2023.
Not included in the provided label excerpts.
Multiple approved products exist for adalimumab (e.g., Hadlima).
Not included in the provided label excerpts.
Enbrel (etanercept) key patents expired in 2029 (U.S.).
Not included in the provided label excerpts.
Biosimilars for etanercept are pending FDA approval.
Not included in the provided label excerpts.
Actemra (tocilizumab) exclusivity/patent period is 2033-2035.
Not included in the provided label excerpts.
There are no biosimilars yet for Actemra.
Not included in the provided label excerpts.
Elderly face 2-3x higher pneumonia risk on biologics.
Not included in the provided label excerpts.
Pneumococcal vaccine is advised for patients on biologics.
Not included in the provided label excerpts.
Non-drug options like PT/OT help mild cases.
Not included in the provided label excerpts.
Start low-go-slow and reassess every 3-6 months.
No such titration/reassessment interval guidance appears in the provided label excerpts.
Contradictions
Low
AI Statement
Hydroxychloroquine for RA and lupus requires no adjustment.
Label Reference
Not directly contradicted by the provided JYLAMVO label excerpts (no hydroxychloroquine statements in label provided).
Important Omissions
Pregnancy-related contraindication and contraception timing (pregnancy testing before initiation; effective contraception during treatment and for 6 months after final dose for females of reproductive potential; males with female partners contraception for at least 3 months after final dose).
Importance:
Moderate
JYLAMVO administration and medication error risk: verify dosing frequency (weekly vs daily errors) and use copackaged syringe/bottle adaptor; teaspoon is not appropriate; oral use only.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Many statements are outside the provided label excerpts and cannot be validated against JYLAMVO prescribing information. However, the only label-anchored safety statements present are general organ-toxicity warnings (e.g., renal toxicity, myelosuppression). The absence of label-supported dosing/threshold guidance reduces confidence and could lead to unsafe clinical decisions if acted upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portions of the response include renal function threshold dosing/avoidance guidance and specific alternative agents/biologic/JAK/vaccine statements that are not supported by the provided JYLAMVO prescribing information excerpts.
Suggested Improvement
Restrict claims to what is explicitly stated in the provided label sections (e.g., contraindications, general warnings/toxicities, and labeled dosage modifications/withhold-discontinue criteria) and avoid adding eGFR/CrCl thresholds, specific combination changes, vaccine recommendations, or other drug-specific statements unless included in the provided labeling.